

# Author's Accepted Manuscript

Adjuvant therapy for high-risk localized kidney cancer– emerging evidence and future clinical trials

Andrew T. Lenis , Nicholas M. Donin , David C. Johnson , Izak Faiena , Amirali Salmasi , Alexandra Drakaki , Arie Beldegrun , Allan Pantuck , Karim Chamie



PII: S0022-5347(17)59380-5  
DOI: [10.1016/j.juro.2017.04.092](https://doi.org/10.1016/j.juro.2017.04.092)  
Reference: JURO 14725

To appear in: *The Journal of Urology*  
Accepted Date: 21 April 2017

Please cite this article as: Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Beldegrun A, Pantuck A, Chamie K, Adjuvant therapy for high-risk localized kidney cancer– emerging evidence and future clinical trials, *The Journal of Urology*® (2017), doi: 10.1016/j.juro.2017.04.092.

**DISCLAIMER:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

## Embargo Policy

**All article content is under embargo until uncorrected proof of the article becomes available online.**

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to [jumedia@elsevier.com](mailto:jumedia@elsevier.com).

Adjuvant therapy for high-risk localized kidney cancer– emerging evidence and future clinical trials

Andrew T. Lenis MD MS<sup>1,2</sup>, Nicholas M. Donin MD<sup>1,2</sup>, David C. Johnson MD MPH<sup>1,2</sup>, Izak Faiena MD<sup>1,2</sup>, Amirali Salmasi MD<sup>1,2</sup>, Alexandra Drakaki MD PhD<sup>1,2,3</sup>, Arie Beldegrun MD<sup>1,2</sup>, Allan Pantuck MD MS<sup>1,2</sup>, Karim Chamie MD MSHS<sup>1,2</sup>

<sup>1</sup>Institute of Urologic Oncology, Department of Urology, University of California Los Angeles

<sup>2</sup>Jonsson Comprehensive Cancer Center, University of California Los Angeles

<sup>3</sup>Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles

Corresponding Author:

Karim Chamie, MD MSHS

300 Stein Plaza, Suite 348

Los Angeles, California 90095

Office: 310-794-2858

Fax: 310-794-3513

Email: [kchamie@mednet.ucla.edu](mailto:kchamie@mednet.ucla.edu)

Abstract Word Count: 347 (limit 350)

Manuscript Word Count: 4,000 (limit 4,000)

References: 49 (limit 50)

Tables: 3

Figure: 1

Keywords (MeSH Terms): Adjuvant; Renal cell carcinoma; Kidney cancer; ASSURE; S-TRAC

ABSTRACT

Download English Version:

<https://daneshyari.com/en/article/8771774>

Download Persian Version:

<https://daneshyari.com/article/8771774>

[Daneshyari.com](https://daneshyari.com)